Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor-Positive and Hormone Receptor-Negative Breast Cancer

被引：8
|
作者：
Mehta, Rita S. [1 ]
Jackson, Donna [1 ]
Schubbert, Toni [1 ]
机构：
[1] Univ Calif Irvine, Dept Med, Div Hematol & Oncol, Irvine, CA 92717 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 18期
关键词：
D O I：
10.1200/JCO.2009.22.9377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3067 / 3068
页数：3
相关论文
共 50 条
  • [1] Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor-Positive and Hormone Receptor-Negative Breast Cancer Reply
    Hugh, Judith
    Hanson, John
    Cheang, Maggie
    Nielsen, Torsten
    Perou, Charles
    Dumontet, Charles
    Reed, John
    Krajewska, Maryla
    Treilleux, Isabelle
    Rupin, Matthieu
    Magherini, Emmanuelle
    Mackey, John
    Martin, Miguel
    Vogel, Charles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 3068 - 3069
  • [2] Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
    Hoon, Siao-Nge
    Lau, Peter K. H.
    White, Alison M.
    Bulsara, Max K.
    Banks, Patricia D.
    Redfern, Andrew D.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (05):
  • [3] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Zheng, Hongjuan
    Ge, Chenyang
    Lin, Haiping
    Wu, Lunpo
    Wang, Qinghua
    Zhou, Shishi
    Tang, Wanfen
    Zhang, Xia
    Jin, Xiayun
    Xu, Xifeng
    Hong, Zhongwu
    Fu, Jianfei
    Du, Jinlin
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1145 - 1153
  • [4] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Hongjuan Zheng
    Chenyang Ge
    Haiping Lin
    Lunpo Wu
    Qinghua Wang
    Shishi Zhou
    Wanfen Tang
    Xia Zhang
    Xiayun Jin
    Xifeng Xu
    Zhongwu Hong
    Jianfei Fu
    Jinlin Du
    [J]. International Journal of Clinical Oncology, 2022, 27 : 1145 - 1153
  • [5] COMPARISON OF CLASSIC AND QUANTITATIVE PROGNOSTIC FACTORS IN HORMONE RECEPTOR-POSITIVE AND HORMONE RECEPTOR-NEGATIVE FEMALE BREAST-CANCER
    AALTOMAA, S
    LIPPONEN, P
    ESKELINEN, M
    KOSMA, VM
    MARIN, S
    ALHAVA, E
    SYRJANEN, K
    [J]. AMERICAN JOURNAL OF SURGERY, 1993, 165 (03): : 307 - 311
  • [6] Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
    Lee, Hee Jin
    Park, In Ah
    Park, So Yeon
    Seo, An Na
    Lim, Bora
    Chai, Yun
    Song, In Hye
    Kim, Na Eun
    Kim, Joo Young
    Yu, Jong Han
    Ahn, Jin-Hee
    Gong, Gyungyub
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (03) : 615 - 623
  • [7] Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
    Hee Jin Lee
    In Ah Park
    So Yeon Park
    An Na Seo
    Bora Lim
    Yun Chai
    In Hye Song
    Na Eun Kim
    Joo Young Kim
    Jong Han Yu
    Jin-Hee Ahn
    Gyungyub Gong
    [J]. Breast Cancer Research and Treatment, 2014, 145 : 615 - 623
  • [8] Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative HER2 normal metastatic breast cancer
    Altundag, Kadri
    [J]. MEDICAL ONCOLOGY, 2024, 41 (06)
  • [9] Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers
    Farhat, Ghada N.
    Cummings, Steven R.
    Chlebowski, Rowan T.
    Parimi, Neeta
    Cauley, Jane A.
    Rohan, Thomas E.
    Huang, Alison J.
    Vitolins, Mara
    Hubbell, F. Allan
    Manson, JoAnn E.
    Cochrane, Barbara B.
    Lane, Dorothy S.
    Lee, Jennifer S.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (07) : 562 - 570
  • [10] Estrogen Receptor Positive and Progesterone Receptor-negative Breast Cancer: The Role of Hormone Therapy
    Habibi, Mehran
    Canner, Joseph
    Dembinski, Robert
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S467 - S467
12345